Skip to content
AnalystLens

Neurocrine Biosciences 8-K Report, Financial Results (Jul 30, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed July 30, 2026
Period End
July 30, 2026
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · Apr ’21Apr ’21
  3. Leadership change8-K · May ’25May ’25

Summary

Summary of the 8-K filed July 30, 2026. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. (NBIX) reported second-quarter 2026 total revenues of $959 milliona, up 39% year over year from $688 million.

INGREZZA net product sales were $716 millionb (up 15%), CRENESSITY net product sales were $184 million (up 247% from $53 million), and VYKAT XR net product sales were $54 million, included from the May 18, 2026 closing of the Soleno Therapeutics acquisition. Unaudited pro forma total revenues including a full quarter of VYKAT XR were $998 million. GAAP net income was $144 million, or $1.39 per diluted share, compared with $108 million, or $1.06, a year earlier.

Non-GAAP net income was $297 millionc, or $2.85 per diluted share, compared with $166 million, or $1.65. The company raised its full-year 2026 INGREZZA net product sales guidance to $2.825 billion to $2.875 billion, from $2.7 billion to $2.8 billion. It also raised GAAP R&D guidance to $1.275 billion to $1.325 billion and GAAP SG&A guidance to $1.575 billion to $1.600 billion, reflecting pipeline investment and commercial spending for the launches.

The Soleno acquisition was completed in May 2026 at $53.00d per share in cash, a total equity value of $2.9 billion. Cash, cash equivalents and marketable securities totaled $482 million at June 30, 2026, down from $2,543 million at December 31, 2025. The company also entered a $1.0 billion senior secured revolving credit facility in May 2026, with the full $1.0 billion available at June 30, 2026.

Management highlighted two Phase 3 readouts expected in 2027 for osavampator in major depressive disorder and direclidine in schizophrenia. The filing states that the press release is furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act.

Key Highlights

  1. Total Q2 2026 revenues of $959 million, up 39% year over year from $688 million; pro forma total revenues of $998 million including a full quarter of VYKAT XR.
  2. INGREZZA Q2 2026 net product sales of $716 million, up 15%, with double-digit prescription volume growth in TRx and record NRx.
  3. CRENESSITY Q2 2026 net product sales of $184 million versus $53 million a year earlier, with approximately 80% reimbursement for dispensed prescriptions.
  4. GAAP diluted EPS of $1.39 and non-GAAP diluted EPS of $2.85 for Q2 2026, compared with $1.06 and $1.65 in Q2 2025.
  5. Full-year 2026 INGREZZA net product sales guidance raised to $2.825 billion to $2.875 billion; GAAP SG&A guidance raised to $1.575 billion to $1.600 billion and GAAP R&D guidance raised to $1.275 billion to $1.325 billion.
  6. Soleno Therapeutics acquisition closed in May 2026 at $53.00 per share in cash ($2.9 billion equity value), adding VYKAT XR; approximately $2.2 billion of intellectual property recorded, amortized over 16 years.
  7. Cash, cash equivalents and marketable securities of $482 million at June 30, 2026, versus $2,543 million at December 31, 2025, with $1.0 billion of revolving credit capacity available.

Frequently Asked Questions

  1. What drove the year-over-year revenue increase in the second quarter of 2026?

    Total revenues rose to $959 million from $688 million, led by INGREZZA ($716 million, up 15%), CRENESSITY ($184 million versus $53 million), and VYKAT XR ($54 million from the May 18, 2026 Soleno closing). The company said higher net product sales accounted for an increase of $272 million.

  2. How did the company's guidance change for 2026?

    INGREZZA net product sales guidance was raised to $2.825 billion to $2.875 billion from $2.7 billion to $2.8 billion. GAAP R&D guidance moved to $1.275 billion to $1.325 billion from $1.2 billion to $1.25 billion, GAAP SG&A guidance to $1.575 billion to $1.600 billion from $1.375 billion to $1.4 billion, and GAAP amortization of acquired intangible assets is now expected at $85 million to $90 million. IPR&D guidance rose to $23 million from $20 million.

  3. What was the Soleno Therapeutics acquisition and how is it reflected in the results?

    Neurocrine acquired Soleno Therapeutics in May 2026 for $53.00 per share in cash, a total equity value of $2.9 billion. The addition of VYKAT XR, a therapy for hyperphagia in Prader-Willi syndrome, is included in results from the May 18, 2026 closing. Acquisition-related costs, including a $58 million acceleration of equity award vesting noted in guidance, are excluded from non-GAAP results.

  4. How did GAAP and non-GAAP earnings compare in the second quarter?

    GAAP net income was $144 million, or $1.39 per diluted share, versus $108 million, or $1.06, a year earlier. Non-GAAP net income was $297 million, or $2.85 per diluted share, versus $166 million, or $1.65. The reconciliation excludes items such as stock-based compensation, acquisition-related costs, and inventory fair value step-up amortization.

  5. What liquidity and financing position did the company report?

    Cash, cash equivalents and marketable securities totaled $482 million at June 30, 2026, compared with $2,543 million at December 31, 2025. In May 2026 the company entered a $1.0 billion senior secured revolving credit facility, with $1.0 billion of borrowing capacity available at June 30, 2026, to provide liquidity for general corporate purposes.